A single dose glycoprotein D-based subunit vaccine against pseudorabies virus infection

文献类型： 外文期刊

第一作者： Zhang, Teng

作者： Zhang, Teng;Zhou, Enmin;Zhang, Gaiping;Zhang, Teng;Liu, Yunchao;Feng, Hua;Wei, Qiang;Zhang, Gaiping;Chen, Yumei;Wang, Aiping;Zhang, Gaiping;Zhang, Gaiping;Zhang, Gaiping

作者机构：

关键词： Pseudorabies virus; Glycoprotein B; Glycoprotein D; Subunit vaccine

期刊名称：VACCINE （ 影响因子：3.641； 五年影响因子：3.816 ）

ISSN： 0264-410X

年卷期： 2020 年 38 卷 39 期

页码：

收录情况： SCI

摘要： Pseudorabies Virus (PRV) is the causative agent of Pseudorabies (PR), also known as Aujeszky's Disease, one of the most important infectious diseases in swine, resulting in huge economic losses to the swine industry globally. The emergence of mutant PRV strains after 2011 resulted in a sharp decrease in the efficacy of available commercial vaccines. To develop a more effective vaccine that can prevent the spread of PRV, glycoprotein B (gB), glycoprotein C (gC) and glycoprotein D (gD) from recent PRV isolates were expressed in a baculovirus system and their protective efficacy was tested in mice and piglets. Neutralizing antibody titers (NAs) in mice vaccinated with gB, gC and gD peaked at 28 days after immunization and then slowly declined. NAs in the mice immunized with gD were remarkably higher than other groups. After a lethal challenge of 5 LD50 with mutant PRV-HNLH strain, the survival rates of gB and gD were 100% and 87.5% respectively, which was significantly higher than gC group (50%). Piglets vaccinated with the gD and gB + D vaccines developed the highest NAs 7 days post immunization. No piglets in these two groups exhibited clinical symptoms, high body temperature or virus shedding following challenge with 10(6.6) TCID50 with the mutant PRV-HNLH strain. Histopathology and immunohistochemistry showed remarkably reduced pathological damage and viral loads in gD and gB + D groups. Furthermore, the duration of the NAs induced by gD vaccine could maintain as long as four months after a single dose. The current study indicates that a gD-based vaccine could be developed for the efficient control of PRV. (C) 2020 Elsevier Ltd. All rights reserved.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序